Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer

Table 3 Specific or targeted anti-angiogenic agents under investigation or approved for metastatic breast cancer

Agent	Class of agent	Target	Stage of development in breast cancer
Bevacizumab	Monoclonal antibody	VEGF	Approved
Pazopanib	TKI	VEGF receptor-1, -2, -3 PDGFR-β c-Kit	III
Sunitinib	TKI	VEGF receptor-1, -2, -3 PDGFR-β c-Kit FLT3 RET CSF-1R	III
Axitinib	TKI	VEGF receptor-1, -2, -3 PDGFR-β c-Kit	II
Sorafenib	TKI	VEGF receptor-2, -3 PDGFR-β c-Kit FLT3 RET Raf	II
Vandetanib	TKI	VEGF receptor-2 RET EGFR	II

CSF-1R, colony-stimulating factor-1 receptor; EGFR, epidermal growth factor receptor; PDGFR, platelet-derived growth factor receptor; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor.

ISSN: 1465-542X